Business
Alternate Health Closes Second Tranche of Financing Agreement
Alternate Health Closes Second Tranche of Financing Agreement.
About this update from Alternate Health Corp
[{"type":"text","content":"\n\n\n\nAlternate Health Closes Second Tranche of Financing Agreement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nAlternate Health Closes Second Tranche of Financing Agreement\nCanada NewsWire\nTORONTO, July 17, 2019\n\n\n\nTORONTO, July 17, 2019 /CNW/ - Alternate Health Corp., (\"Alternate Health\" or the \"Company\") (CSE:AHG) (OTCQB:AHGIF), an international leader in CBD extraction, product development and distribution, announced today that the Company closed the second tranche of its financing arrangement with Alpha Blue Ocean as initially announced on June 14, 2019 and June 17, 2019 (the \"Financing\"), pursuant to the terms of an amended and restated subscription agreement dated July 3, 2019 (the \"Subscription Agreement\").\n\n \n \n\n \nClosing Details\nPursuant to the Subscription Agreement, as part of the closing of the second tranche of the Financing, the Company issued to European High Growth Opportunities Securitization Fund (\"EHGO\") a convertible debenture (the \"Debenture\") in the principal amount of $500,000 and share purchase warrants (the \"Warrants\") exercisable to acquire up to 227,272 common shares of the Company (the \"Shares\") for a period of three years at a price of $0.33 per Share. The Debenture and Warrants otherwise have the terms described in the June 14, 2019 news release. The Debentures and Warrants are subject to a hold period of four months and one day from issuance. Further terms of the Financing are set out in the Subscription Agreement as filed on SEDAR and available under the Company's profile at www.sedar.com. Alternate Health intends to use the funds from the Financing to expand its hemp-derived product line and for general working capital.\nAbout Alternate HealthAlternate Health is an international leader in the hemp-derived CBD industry, including extraction, product development and distribution. Through Alternate Health's subsidiary, Blaine Labs, the Company has 23 years of experience in FDA-registered and cGMP medical product manufacturing and distribution, with over 50 product SKUs available from major retailers, ...